Durect (Durect) Growth Rank

: 2 (As of Today)

View and export this data going back to 2000. Start your Free Trial

Durect has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Durect Growth Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Durect's Growth Rank distribution charts can be found below:

* The bar in red indicates where Durect's Growth Rank falls into.

Durect Growth Rank Related Terms

Thank you for viewing the detailed overview of Durect's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Durect (Durect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

DC8A:Germany

Address

10260 Bubb Road, Cupertino, CA, USA, 95014

Website

https://www.durect.com

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Executives

Judith J. Robertson	director	10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis	director	364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp	officer: Chief Financial Officer	C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia	director	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman	officer: Chief Medical Officer	C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice	officer: Sr. VP Operations & Corp QA	10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe	director	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg	officer: Chief Financial Officer	10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown	director, officer: President & CEO	10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105